Skip to Content


The pharma giant had a banner year in 2019, climbing seven slots on the Fortune 500. Revenue rose almost 11%, to $46.8 billion, while profits leaped 58%, to $9.8 billion. Blockbuster cancer drug Keytruda, as well as an expanded line of animal medicines, have helped power Merck’s growth—though its share price has not seen as much of a lift as some competitors'. More recently, Merck has been notably quiet in medical chatter about the novel coronavirus. But executives on a late April earnings call announced that the company has teams scanning its portfolio of antiviral candidates and vaccine assets for potential treatments.
Brendan McDermid—REUTERS
Created with sketchtool.Leads, insights, and financial data for the FORTUNE 500, FORTUNE 1000, and Global 500 companies.Purchase Now
Lists ranking Merck
Fortune 500 - 2020This year's Fortune 500 marks the 66th running of ...READ MORE
World’s Most Admired Companies - 2020For an astounding 13th straight year, Apple claims...READ MORE